Gemcitabine

Gemcitabine

Clinical data
Routes of administration	Oral, intravenous
ATC code	L01BC05 (WHO)
Pharmacokinetic data
Protein binding	<10%
Elimination half-life	Short infusions 32-94 minutes for long infusions 245-638 minutes
Identifiers
IUPAC name 4-amino-1-[3,3-difluoro-4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl]- 1H-pyrimidin- 2-one
CAS Number	95058-81-4
PubChem CID	60750
DrugBank	APRD00201
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C9H11F2N3O4
Molar mass	263.198 g/mol

WikiDoc Resources for Gemcitabine
Articles
Most recent articles on Gemcitabine Most cited articles on Gemcitabine Review articles on Gemcitabine Articles on Gemcitabine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gemcitabine Images of Gemcitabine Photos of Gemcitabine Podcasts & MP3s on Gemcitabine Videos on Gemcitabine
Evidence Based Medicine
Cochrane Collaboration on Gemcitabine Bandolier on Gemcitabine TRIP on Gemcitabine
Clinical Trials
Ongoing Trials on Gemcitabine at Clinical Trials.gov Trial results on Gemcitabine Clinical Trials on Gemcitabine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gemcitabine NICE Guidance on Gemcitabine NHS PRODIGY Guidance FDA on Gemcitabine CDC on Gemcitabine
Books
Books on Gemcitabine
News
Gemcitabine in the news Be alerted to news on Gemcitabine News trends on Gemcitabine
Commentary
Blogs on Gemcitabine
Definitions
Definitions of Gemcitabine
Patient Resources / Community
Patient resources on Gemcitabine Discussion groups on Gemcitabine Patient Handouts on Gemcitabine Directions to Hospitals Treating Gemcitabine Risk calculators and risk factors for Gemcitabine
Healthcare Provider Resources
Symptoms of Gemcitabine Causes & Risk Factors for Gemcitabine Diagnostic studies for Gemcitabine Treatment of Gemcitabine
Continuing Medical Education (CME)
CME Programs on Gemcitabine
International
Gemcitabine en Espanol Gemcitabine en Francais
Business
Gemcitabine in the Marketplace Patents on Gemcitabine
Experimental / Informatics
List of terms related to Gemcitabine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company.

Pharmacology

Chemically gemcitabine is a nucleoside analog in which the hydrogens on the 2' carbons of deoxycytidine are replaced by fluorides.

As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide").

Indications

Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types. Gemcitabine represents an advance in pancreatic cancer care. It is also not as debilitating as other forms of chemotherapy.

"Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial" reported in the Journal of the American Medical Association (JAMA. 2007;297:239.) suggest that gemcitabine shows benefit in patients with pancreatic cancer who were felt to have successful tumor resections.

Recently, research done at the Anderson Cancer Center in Texas on mice with pancreatic cancer has been done where cromolyn, an allergy and asthma drug with little side effects has been effective in binding with proteins that cancer cells produce. The long term prospects of this new development are very encouraging. Cromolyn is used for asthma, as an eye drop and can be taken orally to treat mastocytosis. The study was published on December 20, 2006 in a leading Cancer journal.

A protein produced by cancerous cells in the pancreas called S100P is found in excess among pancreatic cancer patients and is necessary for cancer cell growth and survival. In addition, S100P activates a cell surface protein receptor called RAGE.

Gemcitabine became first line treatment for bladder cancer Stage 4 with metastases in combination with Cisplatin after a study with 405 patients showed similar efficacy but less toxicity compared to the former MVAC regimen ( J Clin Oncol 2000;18:3068). This new CG-regimen is Cisplatin on day 2, Gemcitabine on days 1,8,15.

External links

• Gemzar.com

de:Gemcitabin gemcitabine is a topo-isomerase tubule inhibitor REF: S. Hussein